Ganzel C, Frisch A, Wolach O, Moshe Y, et al. CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study. Br J Haematol 2025;206:551-555.
PMID: 39721590